Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,725Revenue $M512Net Margin (%)8.4Z-Score10.1
Enterprise Value $M2,282EPS $1.5Operating Margin %12.6F-Score6
P/E(ttm))57.3Cash Flow Per Share $1.3Pre-tax Margin (%)12.9Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %0Quick Ratio3.9Cash flow > EarningsY
Price/Sales4.75-y EBITDA Growth Rate %4.1Current Ratio4.4Lower Leverage y-yY
Price/Cash Flow16.5y-y EBITDA Growth Rate %-60.8ROA % (ttm)4.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)5.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M71.3ROI % (ttm)18.6Gross Margin Increase y-yY

Gurus Latest Trades with IPXL

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IPXLNWQ Managers 2014-09-30 Add0.08%$22.77 - $30.68
($25.55)
$ 38.2450%Add 31.9%1,298,995
IPXLJoel Greenblatt 2014-09-30 Buy 0.01%$22.77 - $30.68
($25.55)
$ 38.2450%New holding, 33709 sh.33,709
IPXLJohn Hussman 2014-09-30 Reduce-0.14%$22.77 - $30.68
($25.55)
$ 38.2450%Reduce -19.35%250,000
IPXLNWQ Managers 2014-06-30 Buy 0.3%$23.6 - $30.68
($26.93)
$ 38.2442%New holding, 984841 sh.984,841
IPXLJohn Hussman 2014-06-30 Add0.21%$23.6 - $30.68
($26.93)
$ 38.2442%Add 40.91%310,000
IPXLJohn Hussman 2014-03-31 Buy 0.44%$22.02 - $27.91
($24.94)
$ 38.2453%New holding, 220000 sh.220,000
IPXLJohn Hussman 2012-03-31 Sold Out -0.11%$18.64 - $24.37
($20.72)
$ 38.2485%Sold Out0
IPXLJoel Greenblatt 2012-03-31 Sold Out -0.05%$18.64 - $24.37
($20.72)
$ 38.2485%Sold Out0
IPXLJoel Greenblatt 2011-12-31 Reduce-0.47%$16.53 - $20.75
($18.65)
$ 38.24105%Reduce -88.51%21,057
IPXLJoel Greenblatt 2011-09-30 Reduce-0.38%$15.26 - $21.56
($19.54)
$ 38.2496%Reduce -40.22%183,187
IPXLJoel Greenblatt 2011-06-30 Add0.76%$20.21 - $28.73
($25.28)
$ 38.2451%Add 446.09%306,452
IPXLGeorge Soros 2011-06-30 Sold Out $20.21 - $28.73
($25.28)
$ 38.2451%Sold Out0
IPXLJohn Hussman 2011-03-31 Add0.02%$20.11 - $25.52
($22.84)
$ 38.2467%Add 20.21%339,000
IPXLGeorge Soros 2011-03-31 Reduce$20.11 - $25.52
($22.84)
$ 38.2467%Reduce -41.13%13,600
IPXLJoel Greenblatt 2011-03-31 Reduce-1.55%$20.11 - $25.52
($22.84)
$ 38.2467%Reduce -78.32%56,118
IPXLJoel Greenblatt 2010-12-31 Buy 1.7%$17.91 - $21.86
($19.9)
$ 38.2492%New holding, 258801 sh.258,801
IPXLJohn Hussman 2010-12-31 Add0.06%$17.91 - $21.86
($19.9)
$ 38.2492%Add 176.47%282,000
IPXLGeorge Soros 2010-12-31 Buy 0.01%$17.91 - $21.86
($19.9)
$ 38.2492%New holding, 23100 sh.23,100
IPXLJohn Hussman 2010-09-30 Buy 0.03%$15.63 - $19.79
($17.38)
$ 38.24120%New holding, 102000 sh.102,000
IPXLGeorge Soros 2010-06-30 Sold Out $16.66 - $21.62
($19.29)
$ 38.2498%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IPXL is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
IPXL Joel Greenblatt 2014-09-3033,7090.050.01New Buy
IPXL NWQ Managers 2014-09-301,298,9951.820.34+31.9%
IPXL John Hussman 2014-09-30250,0000.350.51-19.35%
Premium Most recent portfolio changes are included for Premium Members only!


IPXL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HSU LARRYDirector 2014-06-06Sell100,000$28.3834.74view
TERRERI PETER RDirector 2014-05-27Sell3,000$2836.57view
HSU LARRYDirector 2014-05-22Sell50,000$27.2240.48view
HSU LARRYDirector 2014-05-21Sell3,800$26.5344.14view
TERRERI PETER RDirector 2014-05-20Sell666$26.0746.68view
TERRERI PETER RDirector 2014-05-19Sell950$26.0346.91view
FLEMING NIGELDirector 2014-05-16Sell1,900$25.7248.68view
TERRERI PETER RDirector 2014-05-13Sell666$26.743.22view
FLEMING NIGELDirector 2014-05-12Sell1,333$26.5843.87view
MARKBREITER MICHAELDirector 2014-05-08Sell12,500$26.4444.63view

Press Releases about IPXL :

    Quarterly/Annual Reports about IPXL:

    News about IPXL:

    Articles On GuruFocus.com
    comment on IPXL Sep 24 2012 
    President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
    Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
    Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 
    Impax Laboratories Reports Second Quarter 2009 Financial Results Aug 04 2009 


    More From Other Websites
    Bayer Announces Updates to European Label of Xarelto - Analyst Blog Jan 21 2015
    Bristol-Myers Makes Leadership Changes, Names New CEO - Analyst Blog Jan 21 2015
    Hospira's Plum 36O Infusion System Gets FDA Clearance - Analyst Blog Jan 21 2015
    Teva Up on Positive Copaxone Supreme Court Ruling - Analyst Blog Jan 21 2015
    Agile Therapeutics (AGRX) Soars: Stock Up 15.9% in Session - Tale of the Tape Jan 21 2015
    Actavis/Gedeon Richter Present Schizophrenia Drug Data - Analyst Blog Jan 20 2015
    Corium International (CORI) Jumps: Stock Rises 13.9% - Tale of the Tape Jan 16 2015
    Can the Rally in Impax Laboratories (IPXL) Shares Continue? - Tale of the Tape Jan 15 2015
    IMPAX LABORATORIES INC Files SEC form 8-K, Other Events Jan 14 2015
    Impax Laboratories Expects More M&A After Latest Deal Closes Jan 14 2015
    IMPAX LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 13 2015
    UPDATE 1-Impax's Parkinson's drug gets FDA approval Jan 08 2015
    Impax's Parkinson's drug gets FDA approval Jan 08 2015
    BUZZ-U.S. STOCKS ON THE MOVE-Aeropostale, Ford, Bind Therapeutics Jan 08 2015
    Impax Pharmaceuticals Announce FDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release... Jan 08 2015
    Impax Pharmaceuticals Announce FDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release... Jan 08 2015
    Impax to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 06 2015
    NeuroDerm Rebounds On Parkinson's Disease Drug Data Dec 30 2014
    IMPAX LABORATORIES INC Files SEC form 8-K, Other Events Dec 29 2014
    Impax Laboratories, Inc. -- Moody's Assigns B1 CFR to Impax; Stable Outlook Dec 03 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK